Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyquaternium-42
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Polyquaternium-42 is a cationic polymer belonging to the polyquaternium class of chemicals, primarily utilized as an antimicrobial preservative in ophthalmic formulations and personal care products. It is chemically categorized as a polyquaternary ammonium compound. In clinical research, specifically in studies sponsored by Johnson & Johnson, it has been evaluated as an experimental preservative for over-the-counter (OTC) lubricant eye drops (containing ingredients such as glycerin, hypromellose, and polyethylene glycol 400) intended for the treatment of dry eye. Its mechanism of action relies on its positive charge, which allows it to electrostatically bind to and disrupt the negatively charged cell membranes of bacteria and fungi, thereby maintaining the sterility of multi-dose pharmaceutical products.
- Other names
- polixetonium chloridePoly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylene dichloride]WSCP
Beyond the preview
Go deeper on polyquaternium-42.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyquaternium-42.